Altered brain regional homogeneity is associated with depressive symptoms in COVID-19.
Anxiety
COVID-19
Depression
Fatigue
ReHo
Resting-state fMRI
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
received:
09
02
2022
revised:
31
05
2022
accepted:
22
06
2022
pubmed:
29
6
2022
medline:
20
7
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
COVID-19 is an infectious disease that has spread worldwide in 2020, causing a severe pandemic. In addition to respiratory symptoms, neuropsychiatric manifestations are commonly observed, including chronic fatigue, depression, and anxiety. The neural correlates of neuropsychiatric symptoms in COVID-19 are still largely unknown. A total of 79 patients with COVID-19 (COV) and 17 healthy controls (HC) underwent 3 T functional magnetic resonance imaging at rest, as well as structural imaging. Regional homogeneity (ReHo) was calculated. We also measured depressive symptoms with the Patient Health Questionnaire (PHQ-9), anxiety using the General Anxiety Disorder 7-item scale, and fatigue with the Multidimension Fatigue Inventory. In comparison with HC, COV showed significantly higher depressive scores. Moreover, COV presented reduced ReHo in the left angular gyrus, the right superior/middle temporal gyrus and the left inferior temporal gyrus, and higher ReHo in the right hippocampus. No differences in gray matter were detected in these areas. Furthermore, we observed a negative correlation between ReHo in the left angular gyrus and PHQ-9 scores and a trend toward a positive correlation between ReHo in the right hippocampus and PHQ-9 scores. Heterogeneity in the clinical presentation in COV, the different timing from the first positive molecular swab test to the MRI, and the cross-sectional design of the study limit the generalizability of our findings. Our results suggest that COVID-19 infection may contribute to depressive symptoms via a modulation of local functional connectivity in cortico-limbic circuits.
Sections du résumé
BACKGROUND
COVID-19 is an infectious disease that has spread worldwide in 2020, causing a severe pandemic. In addition to respiratory symptoms, neuropsychiatric manifestations are commonly observed, including chronic fatigue, depression, and anxiety. The neural correlates of neuropsychiatric symptoms in COVID-19 are still largely unknown.
METHODS
A total of 79 patients with COVID-19 (COV) and 17 healthy controls (HC) underwent 3 T functional magnetic resonance imaging at rest, as well as structural imaging. Regional homogeneity (ReHo) was calculated. We also measured depressive symptoms with the Patient Health Questionnaire (PHQ-9), anxiety using the General Anxiety Disorder 7-item scale, and fatigue with the Multidimension Fatigue Inventory.
RESULTS
In comparison with HC, COV showed significantly higher depressive scores. Moreover, COV presented reduced ReHo in the left angular gyrus, the right superior/middle temporal gyrus and the left inferior temporal gyrus, and higher ReHo in the right hippocampus. No differences in gray matter were detected in these areas. Furthermore, we observed a negative correlation between ReHo in the left angular gyrus and PHQ-9 scores and a trend toward a positive correlation between ReHo in the right hippocampus and PHQ-9 scores.
LIMITATIONS
Heterogeneity in the clinical presentation in COV, the different timing from the first positive molecular swab test to the MRI, and the cross-sectional design of the study limit the generalizability of our findings.
CONCLUSIONS
Our results suggest that COVID-19 infection may contribute to depressive symptoms via a modulation of local functional connectivity in cortico-limbic circuits.
Identifiants
pubmed: 35764231
pii: S0165-0327(22)00722-4
doi: 10.1016/j.jad.2022.06.061
pmc: PMC9233546
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-42Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3187-3197
pubmed: 33677642
Mol Psychiatry. 2017 Oct;22(10):1455-1463
pubmed: 27217146
Ann Neurol. 2020 Oct;88(4):851-854
pubmed: 32613682
Compr Psychiatry. 2016 Nov;71:1-10
pubmed: 27567301
J Affect Disord. 2017 Aug 1;217:132-137
pubmed: 28407556
Clin Infect Dis. 2021 Sep 7;73(5):e1089-e1098
pubmed: 33220049
PLoS One. 2013;8(3):e58336
pubmed: 23520499
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Biol Psychiatry. 2002 Jan 1;51(1):59-67
pubmed: 11801231
Front Psychiatry. 2020 Dec 15;11:592467
pubmed: 33384627
BMC Psychiatry. 2021 Jun 1;21(1):280
pubmed: 34074266
Soc Cogn Affect Neurosci. 2013 Feb;8(2):123-33
pubmed: 23051902
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Korean Med Sci. 2020 Dec 07;35(47):e409
pubmed: 33289371
Neuron. 1997 Sep;19(3):613-24
pubmed: 9331352
Proc R Soc Lond B Biol Sci. 1985 Jan 22;223(1232):293-317
pubmed: 2858100
Psychiatry Res. 2020 Dec;294:113461
pubmed: 33038791
Front Psychiatry. 2021 Feb 16;12:618805
pubmed: 33679477
Front Neurosci. 2018 Sep 25;12:661
pubmed: 30319341
Neuropsychopharmacology. 2017 Jan;42(1):242-253
pubmed: 27480575
Neuroimage. 2004 May;22(1):394-400
pubmed: 15110032
Am Psychol. 2020 Jul-Aug;75(5):607-617
pubmed: 32673008
J Affect Disord. 2021 Feb 15;281:91-98
pubmed: 33310451
AJNR Am J Neuroradiol. 2020 Dec;41(12):2199-2203
pubmed: 32883670
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Neuroimage. 2021 Feb 15;227:117666
pubmed: 33359341
J Affect Disord. 2022 Aug 15;311:463-471
pubmed: 35580695
Nature. 2022 Apr;604(7907):697-707
pubmed: 35255491
Front Psychol. 2015 Oct 09;6:1475
pubmed: 26500572
Soc Cogn Affect Neurosci. 2018 Sep 11;13(9):995-1002
pubmed: 30137637
World J Biol Psychiatry. 2015 Oct;16(7):448-71
pubmed: 24635551
Psychosom Med. 2019 Oct;81(8):711-719
pubmed: 31600173
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
Neuroimage. 2015 Oct 1;119:235-51
pubmed: 26123376
Front Psychiatry. 2020 Dec 21;11:626807
pubmed: 33408658
J Affect Disord. 2016 Aug;200:275-83
pubmed: 27155070
Asian J Psychiatr. 2020 Oct;53:102188
pubmed: 32512530
Brain Behav Immun. 2020 Oct;89:594-600
pubmed: 32738287
J Affect Disord. 2019 Feb 15;245:63-71
pubmed: 30368072
J Affect Disord. 2022 Mar 1;300:563-570
pubmed: 34965402
Radiology. 2020 Nov;297(2):E242-E251
pubmed: 32544034
Brain Imaging Behav. 2021 Oct;15(5):2627-2636
pubmed: 33788124
Front Psychol. 2020 Nov 03;11:571828
pubmed: 33224064
Brain Sci. 2020 Dec 19;10(12):
pubmed: 33352638
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
Brain Behav Immun. 2020 Jul;87:49-50
pubmed: 32304883
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Acta Psychiatr Scand. 2021 Dec;144(6):537-552
pubmed: 34292580
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Ann N Y Acad Sci. 2021 Feb;1486(1):90-111
pubmed: 33009668
J Neurosci. 2006 Jan 4;26(1):63-72
pubmed: 16399673
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2823-2833
pubmed: 33501506
Soc Cogn Affect Neurosci. 2019 May 17;14(4):353-365
pubmed: 30874805
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
J Affect Disord. 2013 Sep 25;150(3):727-35
pubmed: 23830141
Neurosci Biobehav Rev. 2014 May;42:9-34
pubmed: 24486722
Brain Behav Immun. 2010 May;24(4):558-63
pubmed: 20043983
Neurosci Biobehav Rev. 2015 Apr;51:77-86
pubmed: 25597656
Healthcare (Basel). 2021 Jun 03;9(6):
pubmed: 34204925
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Virol J. 2021 Aug 14;18(1):168
pubmed: 34391446
Hum Brain Mapp. 2017 Sep;38(9):4788-4805
pubmed: 28608647
Sci Rep. 2021 Aug 9;11(1):16144
pubmed: 34373540
Psychol Med. 2021 Jan;51(2):201-211
pubmed: 33436130
Neurobiol Stress. 2021 May;14:100326
pubmed: 33869679
J Affect Disord. 2018 Mar 15;229:171-176
pubmed: 29316519